Literature DB >> 17313482

Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Alessandra Handisurya1, Sabine Gilch, Dorian Winter, Saeed Shafti-Keramat, Dieter Maurer, Hermann M Schätzl, Reinhard Kirnbauer.   

Abstract

Prion diseases are fatal neurodegenerative disorders caused by proteinaceous infectious pathogens termed prions (PrP(Sc)). To date, there is no prophylaxis or therapy available for these transmissible encephalopathies. Passive immunization with monclonal antibodies recognizing the normal host-encoded prion protein (PrP(C)) has been reported to abolish PrP(Sc) infectivity and to delay onset of disease. Because of established immunologic tolerance against the widely expressed PrP(C), active immunization appears to be difficult to achieve. To overcome this limitation, papillomavirus-like particles were generated that display a nine amino acid B-cell epitope, DWEDRYYRE, of the murine/rat prion protein in an immunogenic capsid surface loop, by insertion into the L1 major capsid protein of bovine papillomavirus type 1. The PrP peptide was selected on the basis of its previously suggested central role in prion pathogenesis. Immunization with PrP-virus-like particles induced high-titer antibodies to PrP in rabbit and in rat, without inducing overt adverse effects. As determined by peptide-specific ELISA, rabbit immune sera recognized the inserted murine/rat epitope and also cross-reacted with the homologous rabbit/human epitope differing in one amino acid residue. In contrast, rat immune sera recognized the murine/rat peptide only. Sera of both species reacted with PrP(C) in its native conformation in mouse brain and on rat pheochromocytoma cells, as determined by immunoprecipitation and fluorescence-activated cell sorting analysis. Importantly, rabbit anti-PrP serum contained high-affinity antibody that inhibited de novo synthesis of PrP(Sc) in prion-infected cells. If also effective in vivo, PrP-virus-like particle vaccination opens a unique possibility for immunologic prevention of currently fatal and incurable prion-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313482      PMCID: PMC3792370          DOI: 10.1111/j.1742-4658.2007.05721.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  50 in total

1.  The Neuroimmune Interface in Prion Diseases.

Authors:  Michael A. Klein; Adriano Aguzzi
Journal:  News Physiol Sci       Date:  2000-10

2.  The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

Authors:  Alexa Ertmer; Sabine Gilch; Seong-Wook Yun; Eckhard Flechsig; Bert Klebl; Matthias Stein-Gerlach; Michael A Klein; Hermann M Schätzl
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

3.  L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.

Authors:  M L De Bruijn; H L Greenstone; H Vermeulen; C J Melief; D R Lowy; J T Schiller; W M Kast
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

4.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

Review 5.  Prion diseases and the immune system.

Authors:  P Aucouturier; R I Carp; C Carnaud; T Wisniewski
Journal:  Clin Immunol       Date:  2000-08       Impact factor: 3.969

6.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

7.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

Authors:  F L Heppner; C Musahl; I Arrighi; M A Klein; T Rülicke; B Oesch; R M Zinkernagel; U Kalinke; A Aguzzi
Journal:  Science       Date:  2001-09-06       Impact factor: 47.728

9.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

10.  Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.

Authors:  Katharina Slupetzky; Saeed Shafti-Keramat; Petra Lenz; Sabine Brandt; Andreas Grassauer; Margit Sara; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

View more
  15 in total

Review 1.  Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19.

Authors:  Nikhil Bhalla; Yuwei Pan; Zhugen Yang; Amir Farokh Payam
Journal:  ACS Nano       Date:  2020-06-26       Impact factor: 15.881

Review 2.  [HPV vaccines. Prophylactic vaccines from virus-like particles].

Authors:  R Kirnbauer
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

3.  [Innovative treatment approaches for Alzheimer's disease. Immunotherapy].

Authors:  R Dodel; M Bacher
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

4.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

Review 5.  Modern uses of electron microscopy for detection of viruses.

Authors:  Cynthia S Goldsmith; Sara E Miller
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

6.  Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease.

Authors:  Fernando Goñi; Candace K Mathiason; Lucia Yim; Kinlung Wong; Jeanette Hayes-Klug; Amy Nalls; Daniel Peyser; Veronica Estevez; Nathaniel Denkers; Jinfeng Xu; David A Osborn; Karl V Miller; Robert J Warren; David R Brown; Jose A Chabalgoity; Edward A Hoover; Thomas Wisniewski
Journal:  Vaccine       Date:  2014-12-21       Impact factor: 3.641

Review 7.  Active and passive immunotherapy for neurodegenerative disorders.

Authors:  David L Brody; David M Holtzman
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

8.  Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

Authors:  Alessandra Handisurya; Ratish Gambhira; Christina Schellenbacher; Saeed Shafti-Keramat; Ola Forslund; Michel Favre; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

9.  High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.

Authors:  F Goñi; F Prelli; F Schreiber; H Scholtzova; E Chung; R Kascsak; D R Brown; E M Sigurdsson; J A Chabalgoity; T Wisniewski
Journal:  Neuroscience       Date:  2008-03-06       Impact factor: 3.590

10.  Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Authors:  Christina Schellenbacher; Richard Roden; Reinhard Kirnbauer
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.